JOP20210338A1 - نظائر 3-(5-مثيل-3،1- ثيازول-2- يل)-n-{(1r)-1-[2-(تراي فلورومثيل) بيريميدين-5-يل] إثيل} بنزاميد - Google Patents

نظائر 3-(5-مثيل-3،1- ثيازول-2- يل)-n-{(1r)-1-[2-(تراي فلورومثيل) بيريميدين-5-يل] إثيل} بنزاميد

Info

Publication number
JOP20210338A1
JOP20210338A1 JOP/2021/0338A JOP20210338A JOP20210338A1 JO P20210338 A1 JOP20210338 A1 JO P20210338A1 JO P20210338 A JOP20210338 A JO P20210338A JO P20210338 A1 JOP20210338 A1 JO P20210338A1
Authority
JO
Jordan
Prior art keywords
compounds
thiazol
benzamide
pyrimidin
analogues
Prior art date
Application number
JOP/2021/0338A
Other languages
English (en)
Inventor
Thede Kai
Pook Elisabeth
Rottmann Antje
Rotgeri Andrea
Ganzer Ursula
Martin Fischer Oliver
Anthony Herbert Simon
Original Assignee
Bayer Pharma AG
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Ag filed Critical Bayer Pharma AG
Publication of JOP20210338A1 publication Critical patent/JOP20210338A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يغطي الاختراع الحالي مركبات من مثبط P2X3 ذات الصيغة العامة (I): (I)، حيث يكون R1 وR2 كما تم تعريفهما هنا، ويغطي طرق لتحضير المركبات المذكورة، والمركبات الوسطية المفيدة لتحضير المركبات المذكورة، وتراكيب صيدلانية وتوليفات تشتمل على المركبات المذكورة، واستخدام المركبات المذكورة لتصنيع التراكيب الصيدلانية للمعالجة أو الوقاية من الأمراض، بالتحديد اضطرابات عصبية المنشأ، كعامل وحيد أو في توليفة مع مقومات نشطة أخرى.
JOP/2021/0338A 2019-06-27 2020-06-25 نظائر 3-(5-مثيل-3،1- ثيازول-2- يل)-n-{(1r)-1-[2-(تراي فلورومثيل) بيريميدين-5-يل] إثيل} بنزاميد JOP20210338A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19182797.1A EP3757103A1 (en) 2019-06-27 2019-06-27 Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases
PCT/EP2020/067828 WO2020260463A1 (en) 2019-06-27 2020-06-25 Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide

Publications (1)

Publication Number Publication Date
JOP20210338A1 true JOP20210338A1 (ar) 2023-01-30

Family

ID=67105828

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0338A JOP20210338A1 (ar) 2019-06-27 2020-06-25 نظائر 3-(5-مثيل-3،1- ثيازول-2- يل)-n-{(1r)-1-[2-(تراي فلورومثيل) بيريميدين-5-يل] إثيل} بنزاميد

Country Status (18)

Country Link
US (1) US20230013419A1 (ar)
EP (2) EP3757103A1 (ar)
JP (1) JP2022538270A (ar)
KR (1) KR20220027860A (ar)
CN (1) CN114026086A (ar)
AU (1) AU2020303269A1 (ar)
BR (1) BR112021024325A2 (ar)
CA (1) CA3145204A1 (ar)
CL (1) CL2021003455A1 (ar)
CO (1) CO2021017435A2 (ar)
CR (1) CR20210686A (ar)
EC (1) ECSP21088111A (ar)
IL (1) IL289161A (ar)
JO (1) JOP20210338A1 (ar)
MA (1) MA56383A (ar)
MX (1) MX2021015853A (ar)
PE (1) PE20220219A1 (ar)
WO (1) WO2020260463A1 (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY192690A (en) 2014-12-09 2022-09-01 Bayer Ag 1,3-thiazol-2-yl substituted benzamides
AU2021282039A1 (en) * 2020-05-25 2022-12-01 The National Institutes of Pharmaceutical R&D Co., Ltd. Arylformamide compound and preparation method and medical use thereof
CN115884970A (zh) * 2020-09-24 2023-03-31 中国医药研究开发中心有限公司 芳基甲酰胺类化合物及其制备方法和医药用途
JP2023543066A (ja) * 2020-09-30 2023-10-12 ヒューマンウェル ヘルスケア （グループ） カンパニー リミテッド ベンザミド類化合物及びその使用
TW202404965A (zh) * 2022-03-29 2024-02-01 大陸商人福醫藥集團股份公司 Ｐ２ｘ３抑制劑化合物及其鹽、多晶型和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008055840A1 (en) * 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Thiazole and oxazole-substituted arylamides
US8501933B2 (en) * 2006-11-09 2013-08-06 Roche Palo Alto Llc Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
SG172190A1 (en) * 2008-12-16 2011-07-28 Hoffmann La Roche Thiadiazole-substituted arylamides
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US10183937B2 (en) * 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
MY192690A (en) 2014-12-09 2022-09-01 Bayer Ag 1,3-thiazol-2-yl substituted benzamides
AU2019269047A1 (en) * 2018-05-15 2020-11-26 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
TWI780329B (zh) * 2018-05-15 2022-10-11 德商拜耳廠股份有限公司 經1,3-噻唑-2-基取代之苯甲醯胺用於治療與神經纖維敏化作用相關疾病之用途

Also Published As

Publication number Publication date
AU2020303269A1 (en) 2022-02-03
IL289161A (en) 2022-02-01
MX2021015853A (es) 2022-02-03
MA56383A (fr) 2022-05-04
EP3757103A1 (en) 2020-12-30
CR20210686A (es) 2022-02-09
CA3145204A1 (en) 2020-12-30
US20230013419A1 (en) 2023-01-19
JP2022538270A (ja) 2022-09-01
EP3990453A1 (en) 2022-05-04
CO2021017435A2 (es) 2022-01-17
KR20220027860A (ko) 2022-03-08
WO2020260463A1 (en) 2020-12-30
CL2021003455A1 (es) 2022-08-05
PE20220219A1 (es) 2022-02-02
BR112021024325A2 (pt) 2022-01-11
ECSP21088111A (es) 2022-01-31
CN114026086A (zh) 2022-02-08

Similar Documents

Publication Publication Date Title
JOP20210338A1 (ar) نظائر 3-(5-مثيل-3،1- ثيازول-2- يل)-n-{(1r)-1-[2-(تراي فلورومثيل) بيريميدين-5-يل] إثيل} بنزاميد
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
PH12017501079A1 (en) 1,3-thiazol-2-yl substituted benzamides
JOP20220131A1 (ar) مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة
NZ734516A (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n’-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
JO3447B1 (ar) 2-(مورفولين-4-يل)-7،1-نفثيريدينات
MX2023009388A (es) Metodos para tratar alteraciones del comportamiento.
MX2022013388A (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activacion inmune.
WO2018077944A3 (en) 4,5-annulated 1,2,4-triazolones
BR112018073951A2 (pt) forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
BR112017010439A2 (pt) composto, composição farmacêutica, combinação farmacêutica, kit, métodos para controle de uma doença fúngica em uma planta e para prevenção ou tratamento de doença fúngica em um indivíduo, e, uso de um composto
PH12020500134A1 (en) Dihydrooxadiazinones
WO2020126968A3 (en) Urea derivatives for use against proliferative diseases
PH12020550494A1 (en) Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
EA201991490A1 (ru) Ароматические амиды карбоновых кислот в качестве антагонистов рецепторов брадикинина в1
BR112021019779A2 (pt) Novo composto e composição para prevenção ou tratamento de doenças respiratórias compreendendo os mesmos como ingrediente ativo
MX2022003830A (es) Compuesto de n-(1h-imidazol-2-il)benzamida y composicion farmaceutica que comprende el mismo como ingrediente activo.
EA202090241A1 (ru) Новые гетероциклические соединения как ингибиторы cdk8/19
AR103645A1 (es) Uso de un depurador de formaldehído en una composición farmacéutica
PL431613A1 (pl) Związek do zastosowania jako lek, inhibitor kinazy PERK oraz jego zastosowanie do zapobiegania i leczenia chorób neurodegeneracyjnych zależnych od stresu retikulum endoplazmatycznego
EA201991016A1 (ru) 2,4,5-трехзамещенные 1,2,4-триазолоны, применяемые в качестве ингибиторов дгодг